Pomerantz LLP is investigating Tyra Biosciences and some of its executives for potential securities fraud following the company's announcement of Phase 2 trial results for its drug dabogratinib. Despite a reported favorable safety profile, a notable percentage of patients experienced serious adverse events, which led to a nearly 18% drop in Tyra's stock price. The investigation aims to determine if the company misled investors about the drug's safety. Investors affected by this are encouraged to contact the law firm for possible class action participation.
The story concerns Tyra Biosciences and an investigation into its drug trial disclosures. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 03:41 WIB: out of 128 health-sector US stocks, 29 rose and 99 fell. Notable movers include Canopy Growth Corp at USD 0.76 with a 7.53% decline and Sana Biotechnology Inc at USD 2.44 down 6.87%.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Nathan's Famous, Inc. is proposed to be sold to Smithfield Foods, Inc. with shareholders set to receive $102 in cash per share. The law firm Kahn Swick & Foti, led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating whether th...
